Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Eli Lilly is the world's most valuable pharmaceutical company by market cap, driven by its dominance in GLP-1 weight loss and diabetes drugs. Mounjaro (tirzepatide) for diabetes and Zepbound for obesity represent a potential $50B+ combined revenue opportunity. The company also has a strong pipeline in Alzheimer's (donanemab) and oncology.
Eli Lilly is at the center of the GLP-1 revolution. Mounjaro/Zepbound supply constraints, prescription growth rates, insurance coverage expansion for weight loss drugs, and competition from Novo Nordisk's next-gen compounds are the key stories. Manufacturing capacity is the primary bottleneck.
Recent WallStreet.AI analysis mentioning Eli Lilly and Company